by Mrudula Kulkarni
3 minutes
Dr. Dennis McBride Joins NRx Pharmaceuticals' Board Of Directors
NRx Pharmaceuticals appoints Dr. Dennis McBride to Board, enhancing neuroscience and digital therapeutics.

NRx Pharmaceuticals, Inc. has appointed Dr. Dennis McBride to its Board of Directors. Dr. McBride has extensive expertise in neuroscience, medical technology, and digital therapeutics, gained from a distinguished career spanning military and private sectors. He retired from the U.S. Navy with a senior flag officer rank and has been a driving force in advancing neuroscience through collaborations with information technology and medical innovation. Dr. McBride also contributed significantly to founding InQTel and other major private sector initiatives.
Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx, said, “I am delighted to welcome Dennis to the Board of NRx. His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients.”
Dr. McBride also expressed his views on joining NRx. He said, “I am proud to join the Board of NRx at such an exciting time for the company – the opportunities have never been greater in Neuroscience to advance and improve novel therapies. I look forward to using my experience to help advance its strategy and further the development of NRx’s impressive pipeline of CNS products and leading its initiative in digital therapeutics.”
Dr. McBride has held significant leadership positions at prominent research institutions such as DARPA and the Naval Research Lab. Following his tenure in the Navy, he served as the head of the Potomac Institute for Policy Studies and as a professor at the National Defense University. He has also provided extensive advisory services to Cabinet Secretaries, Congressional Committees, and corporate executives.
Dr. McBride earned a Ph.D. in experimental psychology along with master's degrees from several esteemed institutions including the Harvard Business School, USC, University of Georgia and the London School of Economics. NRx Pharmaceuticals expects that Dr. McBride's wealth of experience will greatly enhance its efforts in advancing treatments in neuroscience and digital therapeutics.